Objective: The EORTC 55971 trial compared primary debulking surgery (PDS) versus neo-adjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). The impact of both treatment arms on quality of life (QOL) is reported. Methods: Patients with stages IIIc or IV ovarian cancer completed the EORTC QLQ-C30 before treatment, at the third and sixth cycle of chemotherapy, and at 6- and 12-month follow-up. Results: Data of 404 patients (N = 201 PDS arm; N = 203 IDS arm) were included in the QOL analysis. Between treatment arms no statistically significant differences were found in any of the QOL functioning scales. Patients showed a clinically relevant improvement (> 10 points) on the global health/QOL, role functioning, emotional functioning and social functioning scales during and after treatment independent of the type of treatment. Clinically relevant differences from baseline to the follow-up assessments were noted for fatigue, pain, insomnia, appetite loss, constipation, diarrhea indicating symptom control in both treatment arms. Institutions with good QOL compliance were associated with better outcomes. There was a statistical significant difference in the overall debulking status with 39.9% optimal debulking surgery in institutions with good QOL compliance compared to 19.9% in institutions with poor QOL compliance (p = 0.0011). Overall survival (median 32.30 versus 23.29 months; p = 0.0006) and progression free survival (median 12.35 versus 9.92 months; p = 0.0002) were also significantly better. Conclusions: Survival and QOL after NACT followed by surgery was similar to survival and QOL after PDS followed by chemotherapy. However, institutions with good QOL compliance had better survival outcomes.

, , , ,
doi.org/10.1016/j.ygyno.2013.08.014, hdl.handle.net/1765/41354
Gynecologic Oncology
Erasmus MC: University Medical Center Rotterdam

Greimel, E, Kristensen, G.B, van der Burg, M.E.L, Coronado, P, Rustin, G.J.S, del Rio, A.S, … Vergote, I. (2013). Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. Gynecologic Oncology, 1–8. doi:10.1016/j.ygyno.2013.08.014